nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

16.05.2019 | Guidelines

Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group

verfasst von: Riad Salem, Siddharth A. Padia, Marnix Lam, Jon Bell, Carlo Chiesa, Kirk Fowers, Bonnie Hamilton, Joseph Herman, S. Cheenu Kappadath, Thomas Leung, Lorraine Portelance, Daniel Sze, Etienne Garin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

The TheraSphere Global Dosimetry Steering Committee was formed in 2017 by BTG International to review existing data and address gaps in knowledge related to dosimetry. This committee is comprised of health care providers with diverse areas of expertise and perspectives on radiation dosimetry. The goal of these recommendations is to optimize glass microspheres radiation therapy for hepatocellular carcinoma while accounting for variables including disease presentation, tumour vascularity, liver function, and curative/palliative intent. The recommendations aim to unify glass microsphere users behind standardized dosimetry methodology that is simple, reproducible and supported by clinical data, with the overarching goal of improving clinical outcomes and advancing the knowledge of dosimetry.

Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol: JVIR. 2017. https://doi.org/10.1016/j.jvir.2017.04.025.

Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, et al. Hepatobiliary cancers, version 2.2014. J Natl Compr Cancer Netw. 2014;12:1152–82.CrossRef

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155–63.e2. https://doi.org/10.1053/j.gastro.2016.08.029.CrossRefPubMedPubMedCentral

Yttrium S-S. Resin microspheres [package insert]. North Sydney. Australia: SirTex Medical; 2013.

BTG. Insert–TheraSphere P. Yttrium-90 glass microspheres–rev. 12. Biocompatibles UK Ltd, a BTG international group company.

Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210. https://doi.org/10.3389/fonc.2014.00210.CrossRefPubMedPubMedCentral

Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Poree P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68. https://doi.org/10.1007/s00259-013-2395-x.CrossRefPubMedPubMedCentral

Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med: Off Publ, Soc Nucl Med. 2015;56:339–46. https://doi.org/10.2967/jnumed.114.145177.CrossRef

Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102:451–61. https://doi.org/10.1016/j.ijrobp.2018.05.062.CrossRefPubMed

10.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clin Res ed). 2008;336:924–6. https://doi.org/10.1136/bmj.39489.470347.AD.CrossRef

11.

Gates VL, Singh N, Lewandowski RJ, Spies S, Salem R. Intraarterial hepatic SPECT/CT imaging using 99mTc-macroaggregated albumin in preparation for radioembolization. J Nucl Med: Off Publ, Soc Nucl Med. 2015;56:1157–62. https://doi.org/10.2967/jnumed.114.153346.CrossRef

12.

Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43:559–75. https://doi.org/10.1007/s00259-015-3157-8.CrossRefPubMed

13.

Chiesa C, Lambert B, Maccauro M, Ezziddin S, Ahmadzadehfar H, Dieudonne A, et al. Pretreatment dosimetry in HCC radioembolization with (90)Y glass microspheres cannot be invalidated with a bare visual evaluation of (99m)Tc-MAA uptake of colorectal metastases treated with resin microspheres. J Nucl Medi: Off Publ Soc Nucl Med. 2014;55:1215–6. https://doi.org/10.2967/jnumed.113.129361.CrossRef

14.

Ulrich G, Dudeck O, Furth C, Ruf J, Grosser OS, Adolf D, et al. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres. J Nucl Medi: Off Publ Soc Nucl Med. 2013;54:516–22. https://doi.org/10.2967/jnumed.112.112508.CrossRef

15.

Chan K, Alessio A, Johnson G, Vaidya S, Kwan S, Monsky W, et al. Prospective trial using internal pair-production positron emission tomography to establish the Yttrium-90 radioembolization dose required for response of hepatic tumors. Int J Radiat Oncol Biol Phys. 2018;101(2):358–365.

16.

Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Medi: Off Publ Soc Nucl Med. 2009;50:477–84. https://doi.org/10.2967/jnumed.108.056036.CrossRef

17.

International Commission on Radiation Units and Measurements.. Report 85. Fundamental quantities and units for ionizing radiation. J ICRU. 2011;11:1–31. https://doi.org/10.1093/jicru/ndr011.

18.

Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Medi: Off Publ Soc Nucl Med. 2006;47:1209–11.

19.

Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824–45. https://doi.org/10.1118/1.3608909.CrossRefPubMed

20.

Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol: JVIR. 2002;13:S223–9.CrossRefPubMed

21.

Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol: JVIR. 2006;17:1251–78. https://doi.org/10.1097/01.rvi.0000233785.75257.9a.CrossRefPubMed

22.

Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol: JVIR. 2006;17:1425–39. https://doi.org/10.1097/01.rvi.0000235779.88652.53.CrossRefPubMed

23.

Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050–8. https://doi.org/10.1148/radiol.2018171768.

24.

Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, et al. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol: JVIR. 2017;28:777–85.e1. https://doi.org/10.1016/j.jvir.2017.02.018.CrossRefPubMed

25.

Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology. 2016:160718. https://doi.org/10.1148/radiol.2016160718.

26.

Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163–71. https://doi.org/10.1016/j.ijrobp.2009.10.062.CrossRefPubMed

27.

Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol: JVIR. 2014;25:1067–73. https://doi.org/10.1016/j.jvir.2014.03.030.CrossRefPubMed

28.

Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatol (Baltimore, Md). 2014;60:192–201. https://doi.org/10.1002/hep.27057.CrossRef

29.

Ali R, Riaz A, Gabr A, Abouchaleh N, Mora R, Al Asadi A, et al. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging. 2017;44:2195–202. https://doi.org/10.1007/s00259-017-3792-3.CrossRefPubMed

30.

Johnson GE, Monsky WL, Valji K, Hippe DS, Padia SA. Yttrium-90 Radioembolization as a salvage treatment following chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol: JVIR. 2016;27:1123–9. https://doi.org/10.1016/j.jvir.2016.03.046.CrossRefPubMed

31.

Gates VL, Hickey R, Marshall K, Williams M, Salzig K, Lewandowski RJ, et al. Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction? Eur J Nucl Med Mol Imaging. 2015;42:2038–44. https://doi.org/10.1007/s00259-015-3122-6.CrossRefPubMed

32.

Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiograph: Rev Publ Radiol Soc North Am, Inc. 2008;28:81–99. https://doi.org/10.1148/rg.281065721.CrossRef

33.

Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57:421–9. https://doi.org/10.1016/j.jhep.2012.01.031.CrossRefPubMed

34.

Louie JD, Kothary N, Kuo WT, Hwang GL, Hofmann LV, Goris ML, et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol: JVIR. 2009;20:606–13. https://doi.org/10.1016/j.jvir.2009.01.021.CrossRefPubMed

35.

Hamoui N, Minocha J, Memon K, Sato K, Ryu R, Salem R, et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol. 2013;24:1743–5. https://doi.org/10.1016/j.jvir.2013.07.011.CrossRefPubMed

36.

Kallini JR, Gabr A, Kulik L, Salem R, Lewandowski RJ. The utility of unilobar technetium-99m macroaggregated albumin to predict pulmonary toxicity in bilobar hepatocellular carcinoma prior to Yttrium-90 radioembolization. J Vasc Interv Radiol. 2016;27:1453–6. https://doi.org/10.1016/j.jvir.2016.06.004.CrossRefPubMed

37.

Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–92. https://doi.org/10.1007/s00270-007-9064-z.CrossRefPubMed

38.

Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, et al. Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging. 2016;43:2353–9. https://doi.org/10.1007/s00259-016-3438-x.CrossRefPubMed

39.

Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141:526–35.e2. https://doi.org/10.1053/j.gastro.2011.04.054.CrossRefPubMedPubMedCentral

40.

Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses. Hepatol (Baltimore, Md). 2018;67:873–83. https://doi.org/10.1002/hep.29480.CrossRef

41.

Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114:99–105. https://doi.org/10.1002/jso.24269.CrossRefPubMed

42.

Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59:1029–36. https://doi.org/10.1016/j.jhep.2013.06.015.CrossRefPubMedPubMedCentral

43.

Braat M, de Jong HW, Seinstra BA, Scholten MV, van den Bosch M, Lam M. Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res. 2017;7:2. https://doi.org/10.1186/s13550-016-0248-x.CrossRefPubMedPubMedCentral

44.

Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2017;45(3):392-401. https://doi.org/10.1007/s00259-017-3845-7.

45.

Spreafico C, Maccauro M, Mazzaferro V, Chiesa C. The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging. 2014;41:634–8. https://doi.org/10.1007/s00259-013-2674-6.CrossRefPubMed

46.

Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, et al. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518–25. https://doi.org/10.1245/s10434-013-2906-9.CrossRefPubMed

47.

Vouche M, Degrez T, Bouazza F, Delatte P, Galdon MG, Hendlisz A, et al. Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. World J Hepatol. 2017;9:1372–7. https://doi.org/10.4254/wjh.v9.i36.1372.CrossRefPubMedPubMedCentral

48.

Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Quart J Nucl Med Mol Imaging : Off Publ Italian Assoc Nucl Med (AIMN) [and] Int Assoc Radiopharmacol (IAR), [and] Sect So. 2011;55:168–97.

49.

Chan KT, Alessio AM, Johnson GE, Vaidya S, Kwan SW, Monsky W, et al. Hepatotoxic dose thresholds by positron-emission tomography after Yttrium-90 Radioembolization of liver tumors: a prospective single-arm observational study. Cardiovasc Intervent Radiol. 2018;41(9):1363-1372. https://doi.org/10.1007/s00270-018-1949-5.

50.

Gil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatol (Baltimore, Md). 2013;57:1078–87. https://doi.org/10.1002/hep.26191.CrossRef

51.

Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Institutional decision to adopt Y90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatol (Baltimore, Md). 2017. https://doi.org/10.1002/hep.29691.

52.

Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64. https://doi.org/10.1053/j.gastro.2009.09.006.CrossRefPubMed

53.

Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatol (Baltimore, Md). 2013;57:1826–37. https://doi.org/10.1002/hep.26014.CrossRef

54.

Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, et al. Correlation of technetium-99m macroaggregated albumin and Yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography/CT. J Vasc Interv Radiol: JVIR. 2017;28:722–30.e1. https://doi.org/10.1016/j.jvir.2016.12.1221.CrossRefPubMed

55.

Balagopal A, Kappadath C. Characterization of 90Y-SPECT/CT self-calibration approaches on the quantification of voxel-level absorbed doses following 90Y-microsphere selective internal radiation therapy. Med Phys. 2017. https://doi.org/10.1002/mp.12695.

56.

Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42:1718–38. https://doi.org/10.1007/s00259-015-3068-8.CrossRefPubMed

57.

Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with. Liver Int. 2017;37:101–10. https://doi.org/10.1111/liv.13220.CrossRefPubMed

58.

Seidensticker R, Seidensticker M, Damm R, Mohnike K, Schütte K, Malfertheiner P, et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol. 2012;35:1109–18. https://doi.org/10.1007/s00270-011-0295-7.CrossRefPubMed

59.

Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27:526–35. https://doi.org/10.1007/s00330-016-4445-9.CrossRefPubMed

60.

Abouchaleh N, Gabr A, Ali R, Al Asadi A, Mora RA, Kallini JR, et al. Y90 Radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Medi: Off Publ Soc Nucl Med. 2017. https://doi.org/10.2967/jnumed.117.199752.

61.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–36. https://doi.org/10.1016/s1470-2045(17)30683-6.CrossRefPubMed

62.

Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36:1913–21. https://doi.org/10.1200/jco.2017.76.0892.CrossRef

63.

Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73–80. https://doi.org/10.1016/j.jhep.2012.09.003.CrossRefPubMed

64.

Mikell JK, Mahvash A, Siman W, Baladandayuthapani V, Mourtada F, Kappadath SC. Selective internal radiation therapy with Yttrium-90 glass microspheres: biases and uncertainties in absorbed dose calculations between clinical dosimetry models. Int J Radiat Oncol Biol Phys. 2016;96:888–96. https://doi.org/10.1016/j.ijrobp.2016.07.021.CrossRefPubMedPubMedCentral

65.

Ho CL, Chen S, Cheung SK, Leung YL, Cheng KC, Wong KN, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET/CT and posttreatment (90)Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4064-6.

Titel: Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group
verfasst von: Riad Salem
Siddharth A. Padia
Marnix Lam
Jon Bell
Carlo Chiesa
Kirk Fowers
Bonnie Hamilton
Joseph Herman
S. Cheenu Kappadath
Thomas Leung
Lorraine Portelance
Daniel Sze
Etienne Garin
Publikationsdatum: 16.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04340-5

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [18F]-FDG PET/CT

Diagnosing fracture-related infections: can we optimize our nuclear imaging techniques?

Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study

3′-Deoxy-3’-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies

[18F]FDG PET/CT in non-union: improving the diagnostic performances by using both PET and CT criteria

Transfer of yttrium-90 to breast milk during radiosynoviorthesis of the knee joint